LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 295

Search options

  1. Book: Therapie-Handbuch - Rheumatologie und Immunologie

    Distler, Jörg Hans Wilhelm

    2022  

    Author's details Jörg H.W. Distler (Hrsg.) ; mit Beiträgen von: Martin Arbogast (Oberammergau) [und weiteren]
    Keywords Fibromyalgie ; Lupus erythematodes ; Osteoporose ; Sjögren-Syndrom ; Rheuma ; Arthritis ; Spondyloarthritis ; Systemische Sklerodermie ; Rheumatismus
    Subject Rheuma ; Rheumatische Krankheit
    Language German
    Size XVI, 264 Seiten, Illustrationen, 27 cm x 21 cm
    Edition 1. Auflage
    Publisher Elsevier
    Publishing place München
    Publishing country Germany
    Document type Book
    HBZ-ID HT021338904
    ISBN 978-3-437-23884-0 ; 3-437-23884-1 ; 9783437060250 ; 3437060252
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Reply.

    Distler, Jörg H W / Hallén, Jonas

    Arthritis & rheumatology (Hoboken, N.J.)

    2024  

    Language English
    Publishing date 2024-02-13
    Publishing country United States
    Document type Letter
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42823
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: A broad look into the future of systemic sclerosis.

    Riemekasten, Gabriela / Distler, Jörg H W

    Therapeutic advances in musculoskeletal disease

    2022  Volume 14, Page(s) 1759720X221109404

    Abstract: Systemic sclerosis (SSc) is a systemic autoimmune disease with the key features of inflammation, vasculopathy and fibrosis. This article focussed on emerging fields based on the authors' current work and expertise. The authors provide a hierarchical ... ...

    Abstract Systemic sclerosis (SSc) is a systemic autoimmune disease with the key features of inflammation, vasculopathy and fibrosis. This article focussed on emerging fields based on the authors' current work and expertise. The authors provide a hierarchical structure into the studies of the pathogenesis of SSc starting with the contribution of environmental factors. Regulatory autoantibodies (abs) are discussed, which are parts of the human physiology and are specifically dysregulated in SSc. Abs against the angiotensin II receptor subtype 1 (AT1R) and the endothelin receptor type A (ETAR) are discussed in more detail. Extracellular vesicles are another novel player to possess disease processes. Fibroblasts are a key effector cell in SSc. Therefore, the current review will provide an overview about their plasticity in the phenotype and function. Promising nuclear receptors as key regulators of transcriptional programmes will be introduced as well as epigenetic modifications, which are pivotal to maintain the profibrotic fibroblast phenotype independent of external stimuli. Fibroblasts from SSc patients exhibit a specific signalling and reactivate developmental pathways and stem cell maintenance such as by employing hedgehog and WNT, which promote fibroblast-to-myofibroblast transition and extracellular matrix generation. Pharmacological interventions, although for other indications, are already in clinical use to address pathologic signalling.
    Language English
    Publishing date 2022-08-09
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516075-8
    ISSN 1759-7218 ; 1759-720X
    ISSN (online) 1759-7218
    ISSN 1759-720X
    DOI 10.1177/1759720X221109404
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Exciting Future for Scleroderma: What Therapeutic Pathways Are on the Horizon?

    Distler, Jörg H W / Riemekasten, Gabriela / Denton, Christopher P

    Rheumatic diseases clinics of North America

    2023  Volume 49, Issue 2, Page(s) 445–462

    Abstract: Emerging evidence shows that a complex interplay between cells and mediators and extracellular matrix factors may underlie the development and persistence of fibrosis in systemic sclerosis. Similar processes may determine vasculopathy. This article ... ...

    Abstract Emerging evidence shows that a complex interplay between cells and mediators and extracellular matrix factors may underlie the development and persistence of fibrosis in systemic sclerosis. Similar processes may determine vasculopathy. This article reviews recent progress in understanding how fibrosis becomes profibrotic and how the immune system, vascular, and mesenchymal compartment affect disease development. Early phase trials are informing about pathogenic mechanisms in vivo and reverse translation for observational and randomized trials is allowing hypotheses to be developed and tested. In addition to repurposing already available drugs, these studies are paving the way for the next generation of targeted therapeutics.
    MeSH term(s) Humans ; Scleroderma, Systemic/drug therapy ; Fibrosis
    Language English
    Publishing date 2023-03-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92118-x
    ISSN 1558-3163 ; 0889-857X
    ISSN (online) 1558-3163
    ISSN 0889-857X
    DOI 10.1016/j.rdc.2023.01.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Reply.

    Soare, Alina / Distler, Jörg H W

    Arthritis & rheumatology (Hoboken, N.J.)

    2020  Volume 73, Issue 1, Page(s) 179–180

    MeSH term(s) Fibroblasts ; Fibrosis ; Humans ; Scleroderma, Systemic
    Language English
    Publishing date 2020-11-17
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.41467
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease.

    Liang, Minrui / Matteson, Eric L / Abril, Andy / Distler, Jörg H W

    Therapeutic advances in musculoskeletal disease

    2022  Volume 14, Page(s) 1759720X221074457

    Abstract: The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved ... ...

    Abstract The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the phase III INBUILD trial demonstrated beneficial effects of nintedanib in RA-ILD with a progressive phenotype by reducing the rate of decline in forced vital capacity (FVC) over 52 weeks by 60%. Pirfenidone is another antifibrotic agent currently under phase II clinical study (TRAIL1) aiming to evaluate its effects for RA-ILD. This review provides an overview of state-of-the-art pathogenesis and the current therapeutic options for RA-ILD, with a focus on antifibrotic strategies.
    Language English
    Publishing date 2022-02-15
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516075-8
    ISSN 1759-7218 ; 1759-720X
    ISSN (online) 1759-7218
    ISSN 1759-720X
    DOI 10.1177/1759720X221074457
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Mouse Models of Skin Fibrosis.

    Rius Rigau, Aleix / Luber, Markus / Distler, Jörg H W

    Methods in molecular biology (Clifton, N.J.)

    2021  Volume 2299, Page(s) 371–383

    Abstract: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality. The first histopathological hallmarks are vasculopathy and inflammation, followed by fibrosis of the skin and internal organs. The molecular and cellular ... ...

    Abstract Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality. The first histopathological hallmarks are vasculopathy and inflammation, followed by fibrosis of the skin and internal organs. The molecular and cellular mechanisms are incompletely understood. Rodent models provide important insights into the pathogenesis of SSc and are a mainstay for the development of novel targeted therapies. Here we describe the mechanistic insights of inducible and genetic models, and also discuss in detail the limitations and pitfalls of the most frequently used SSc mouse models. We also describe protocols for running the established bleomycin-induced scleroderma skin fibrosis model.
    MeSH term(s) Animals ; Bleomycin/adverse effects ; Disease Models, Animal ; Fibrosis ; Graft vs Host Disease/genetics ; Graft vs Host Disease/pathology ; Humans ; Mice ; Scleroderma, Systemic/chemically induced ; Scleroderma, Systemic/pathology ; Skin/pathology
    Chemical Substances Bleomycin (11056-06-7)
    Language English
    Publishing date 2021-05-24
    Publishing country United States
    Document type Journal Article
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-0716-1382-5_25
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis.

    Distler, Jörg H W / O'Reilly, Steven

    Annals of the rheumatic diseases

    2021  Volume 81, Issue 2, Page(s) 151–152

    MeSH term(s) Epigenesis, Genetic ; Fibroblasts ; Humans ; Scleroderma, Systemic/genetics
    Language English
    Publishing date 2021-11-29
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2021-221605
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Cellular and molecular mechanisms in fibrosis.

    Dees, Clara / Chakraborty, Debomita / Distler, Jörg H W

    Experimental dermatology

    2020  Volume 30, Issue 1, Page(s) 121–131

    Abstract: The activation of fibroblasts is required for physiological tissue remodelling such as wound healing. However, when the regulatory mechanisms are disrupted and fibroblasts remain persistently activated, the progressive deposition of extracellular matrix ... ...

    Abstract The activation of fibroblasts is required for physiological tissue remodelling such as wound healing. However, when the regulatory mechanisms are disrupted and fibroblasts remain persistently activated, the progressive deposition of extracellular matrix proteins leads to tissue fibrosis, which results in dysfunction or even loss of function of the affected organ. Although fibrosis has been recognized as a major cause of morbidity and mortality in modern societies, there are only few treatment options available that directly disrupt the release of extracellular matrix from fibroblasts. Intensive research in recent years, however, identified several pathways as core fibrotic mechanisms that are shared across different fibrotic diseases and organs. We discuss herein selection of those core pathways, especially downstream of the profibrotic TGF-β pathway, which are druggable and which may be transferable from bench to bedside.
    MeSH term(s) Animals ; DNA Methylation ; Ephrins/metabolism ; Fibroblast Growth Factor 9/metabolism ; Fibrosis/genetics ; Fibrosis/metabolism ; Fibrosis/pathology ; Guanylate Cyclase/metabolism ; Histone Code ; Humans ; Idiopathic Pulmonary Fibrosis/genetics ; Idiopathic Pulmonary Fibrosis/metabolism ; Idiopathic Pulmonary Fibrosis/pathology ; Janus Kinases/metabolism ; Myofibroblasts ; Receptors, Cytoplasmic and Nuclear/metabolism ; STAT Transcription Factors/metabolism ; Scleroderma, Systemic/genetics ; Scleroderma, Systemic/metabolism ; Scleroderma, Systemic/pathology ; Serotonin/metabolism ; Signal Transduction ; Skin/pathology ; Transforming Growth Factor beta/metabolism
    Chemical Substances Ephrins ; Fibroblast Growth Factor 9 ; Receptors, Cytoplasmic and Nuclear ; STAT Transcription Factors ; Transforming Growth Factor beta ; Serotonin (333DO1RDJY) ; Janus Kinases (EC 2.7.10.2) ; Guanylate Cyclase (EC 4.6.1.2)
    Language English
    Publishing date 2020-10-09
    Publishing country Denmark
    Document type Journal Article ; Review
    ZDB-ID 1130936-2
    ISSN 1600-0625 ; 0906-6705
    ISSN (online) 1600-0625
    ISSN 0906-6705
    DOI 10.1111/exd.14193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Response to: 'Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'' by Jeny

    Györfi, Andrea Hermina / Schett, Georg / Distler, Jörg H W

    Annals of the rheumatic diseases

    2020  Volume 81, Issue 12, Page(s) e242

    MeSH term(s) Humans ; Glucocorticoids/therapeutic use ; COVID-19 ; Sarcoidosis/complications ; Sarcoidosis/drug therapy ; Recurrence
    Chemical Substances Glucocorticoids
    Keywords covid19
    Language English
    Publishing date 2020-10-01
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-218983
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top